Updated on 6 August 2026
(DISEASE-14) GMP/IMP supply and early-phase trial delivery for neurodegenerative-disease interventions
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
About
ELPEN Pharmaceutical and its affiliated Athens LifeTech Park (Greece) offer manufacturing and trial-delivery capability to HORIZON-HLTH-2027-02-DISEASE-14.
Where the intervention's active substance requires manufacturing, ELPEN can produce and release the investigational medicinal product (IMP) to GMP standard, provide formulation/dosage-form development, and support trial conduct, regulatory pathway and pharmacovigilance.
Via Athens LifeTech Park, the group delivers Phase 1/2 trials through its early-phase clinical CRO (Phase 0–II) with Greek/EU site management and registry-powered recruitment, and provides bioanalysis/PK (LC-MS/MS) and molecular biomarker measurement (qPCR, protein analysis).
Note: ELPEN/ALTP is a manufacturing and trial-delivery partner, not a neurodegenerative-disease specialist, and does not own a candidate intervention or provide imaging/omics/AI capability. We are therefore seeking a clinical/scientific lead with the candidate intervention and neuro expertise. ALTP's incubator can bring qualifying SMEs.
Topic
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
Organisation
Similar opportunities
Project cooperation
(TOOL-01) Real-world NCD data and clinical validation for AI-biomarker development
- Partner seeks Consortium/Coordinator
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
Project cooperation
(CANCER-03) GMP manufacturing and first-in-human trial delivery for rare-cancer therapeutics
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece
Project cooperation
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece